Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Aug. 25 and Sept 2. Deal Watch is supported by deal intelligence from Strategic Transactions.
Unraveling a complication left over from its 2012 acquisition of bispecific T-cell engager (BiTE) specialist Micromet Inc., Amgen Inc. announced on Sept